September 29, 2022
4D pharma will not report it’s half year interim results
4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
June 14, 2022
ProBiotix Health with new CEO
ProBiotix Health, a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherosclerosis, has appointed Steen Andersen as Chief Executive Officer.
June 14, 2022
FDA lifts clinical hold on Homology Medicines’ pheNIX trial
The U.S. Food and Drug Administration (FDA) has notified Homology that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been lifted.
June 3, 2022
Novartis’ Kisqali the only CDK4/6 inhibitor consistent significant overall survival across entire Phase III program
Novartis today announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer. These data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis said.
April 26, 2022
Aperion Biologics create invIOs Holding through demerger
APEIRON Biologics AG has announced that the annual general meeting held yesterday has approved the new structure of the group…
April 22, 2022
Ultimovacs’ combination immunotherapies in cancer validated by the USPTO
Ultimovacs ASA has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application 16/306,352 on the use of vaccine-checkpoint inhibitor combinations to treat cancer.
April 12, 2022
IO Biotech doses first patient in metastatic nsclc in phase 2, combining its candidate with Keytruda
IO Biotech, a clinical-stage biopharmaceutical company has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its…
April 11, 2022
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), has announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.
April 10, 2022
Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
April 10, 2022
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
Affimed N.V. (Nasdaq: AFMD) has provided a data update from the ongoing study of the company’s lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.